EVGN Stock Overview
Evogene Ltd., together with its subsidiaries, operates as a computational biology company.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evogene Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪2.59 |
| 52 Week High | ₪6.10 |
| 52 Week Low | ₪1.89 |
| Beta | 1.16 |
| 1 Month Change | -10.09% |
| 3 Month Change | -13.19% |
| 1 Year Change | 18.41% |
| 3 Year Change | -82.31% |
| 5 Year Change | -62.71% |
| Change since IPO | -77.64% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 05
Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Oct 09Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Jun 26We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 13Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation
Oct 07We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Jun 16Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Mar 02Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation
May 28Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth
Jan 21
What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?
Nov 30Shareholder Returns
| EVGN | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -0.2% | 3.2% | 2.9% |
| 1Y | 18.4% | 4.6% | 10.8% |
Return vs Industry: EVGN exceeded the IL Biotechs industry which returned 2.1% over the past year.
Return vs Market: EVGN exceeded the IL Market which returned 10.7% over the past year.
Price Volatility
| EVGN volatility | |
|---|---|
| EVGN Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months.
Volatility Over Time: EVGN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
| EVGN fundamental statistics | |
|---|---|
| Market cap | ₪131.22m |
| Earnings (TTM) | -₪89.98m |
| Revenue (TTM) | ₪21.25m |
6.2x
P/S Ratio-1.5x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVGN income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$1.69m |
| Gross Profit | US$3.95m |
| Other Expenses | US$27.83m |
| Earnings | -US$23.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 70.00% |
| Net Profit Margin | -423.39% |
| Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparison